Galderma Group AG Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	5,241	4,440	4,117
Revenue Growth (YoY)	18.04%	7.85%	-
Cost of Revenue	1,632	1,355	1,232
Gross Profit	3,609	3,085	2,885
Selling, General & Admin	2,240	1,920	1,759
Research & Development	245	260	287
Other Operating Expenses	296	260	303
Total Operating Expenses	2,781	2,440	2,349
Operating Income	829	645	536
Interest Income	13	46	38
Interest Expense	-203	-374	-564
Other Non-Operating Income (Expense)	0	-7	2
Total Non-Operating Income (Expense)	-190	-335	-524
Pretax Income	638	310	11
Provision for Income Taxes	26	79	68
Net Income	613	231	-57
Net Income to Common	613	231	-57
Net Income Growth	165.37%	-	-
Shares Outstanding (Basic)	236	238	238
Shares Outstanding (Diluted)	237	238	238
Shares Change (YoY)	-0.34%	0.10%	-
EPS (Basic)	2.60	0.97	-0.24
EPS (Diluted)	2.58	0.97	-0.24
EPS Growth	165.98%	-	-
Free Cash Flow	1,072	360	44
Free Cash Flow Growth	197.78%	718.18%	-
Free Cash Flow Per Share	4.52	1.51	0.19
Dividends Per Share	0.441	0.166	-
Dividend Growth	166.65%	-	-
Gross Margin	68.86%	69.48%	70.08%
Operating Margin	15.82%	14.53%	13.02%
Profit Margin	11.70%	5.20%	-1.38%
FCF Margin	20.45%	8.11%	1.07%
EBITDA	1,152	938	812
EBITDA Margin	21.98%	21.13%	19.72%
EBIT	829	645	536
EBIT Margin	15.82%	14.53%	13.02%
Effective Tax Rate	4.08%	25.48%	618.18%